Janney Montgomery Scott LLC Purchases 246 Shares of Integer Holdings Co. (NYSE:ITGR)

Janney Montgomery Scott LLC raised its position in shares of Integer Holdings Co. (NYSE:ITGR) by 2.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,668 shares of the medical equipment provider’s stock after purchasing an additional 246 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Integer were worth $1,257,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Contravisory Investment Management Inc. raised its holdings in Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 80 shares during the last quarter. Quest Partners LLC raised its stake in shares of Integer by 3,688.9% in the second quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 332 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Integer by 60.9% during the second quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 142 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Integer during the first quarter valued at $106,000. Finally, Innealta Capital LLC bought a new stake in Integer in the 2nd quarter worth about $110,000. 99.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on ITGR shares. Bank of America lifted their price target on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Citigroup boosted their target price on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research note on Tuesday, October 1st. Truist Financial dropped their price target on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. KeyCorp lifted their price objective on Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Finally, Piper Sandler reissued an “overweight” rating and issued a $140.00 target price (up from $125.00) on shares of Integer in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Trading Down 1.9 %

Shares of ITGR opened at $134.91 on Friday. Integer Holdings Co. has a fifty-two week low of $84.75 and a fifty-two week high of $140.91. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.09 and a current ratio of 3.28. The company’s fifty day moving average is $129.02 and its 200 day moving average is $122.37. The stock has a market capitalization of $4.52 billion, a PE ratio of 42.15, a P/E/G ratio of 1.97 and a beta of 1.09.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The firm had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same quarter last year, the firm earned $1.27 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. Sell-side analysts expect that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.